SCHEMBL25914401

SCHEMBL25914401

O=S(=O)(O)Cc1nnc(-c2ccc(Br)cc2)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
MAPT P10636 5/20 0.49
POLB P06746 3/20 0.49
HTT P42858 2/20 0.49
PTK2 Q05397 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 3/20 0.47
CYP1A2 P05177 3/20 0.47
MEN1 O00255 2/20 0.47
DGAT1 O75907 1/20 0.47
PTGS2 P35354 1/20 0.47
HPGD P15428 4/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
KDM4E B2RXH2 5/20 0.44
TP53 P04637 3/20 0.44
LMNA P02545 3/20 0.44
TSHR P16473 5/20 0.43
HSD17B10 Q99714 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25914399 0.84 TSHR (0.63) NPC1RAB9APOLBHPGDSMN1; SMN2
SCHEMBL25914400 0.84 MAOB (0.53) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL28494999 0.78 NOTUM (0.68) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL30889117 0.76 NPC1 (0.63) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL30889116 0.76 NPC1 (0.63) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL15912496 0.75 MAPT (0.55) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL25914397 0.75 HDAC6 (0.48) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL8589773 0.75 NPC1 (0.61) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL5117429 0.75 ALDH1A1 (0.68) NPC1RAB9AL3MBTL1MAPTPOLB
SCHEMBL9610048 0.73 DGAT1 (0.72) NPC1RAB9AL3MBTL1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A NPC1 1348/4885RAB9A 2204/4885L3MBTL1 2454/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A NPC1 1348/4885RAB9A 2204/4885L3MBTL1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.